Alibhai, A. Yasin
Mehta, Nihaal
Hickson-Curran, Sheila
Moreira-Neto, Carlos
Levine, Emily S.
Reichel, Elias
Duker, Jay S.
Waheed, Nadia K.
Funding for this research was provided by:
Janssen Pharmaceuticals
Article History
Received: 20 January 2020
Accepted: 11 April 2020
First Online: 30 April 2020
Competing interests
: Sheila Hickson-Curran: Janssen Pharmaceutical Companies of Johnson & Johnson (Employee). Nadia K. Waheed: Massachusetts Lions Club (Financial Support), Nidek Medical Products (Speaker fee), Genentech/Roche (Consultant), Topcon Medical Systems, Inc (Consultant), Regeneron (Consultant), Apellis (Consultant), Astellas (Consultant), Boehringer Ingelheim (Consultant), Novartis (Consultant), Optovue Inc (Consultant), Carl Zeiss Meditec Inc (Consultant), Janssen Pharmaceutical Companies of Johnson & Johnson (Consultant), Gyroscope (Officer of Entity), Boston Image Reading Center (Stock), Ocudyne (Stock). Jay S. Duker: Research to Prevent Blindness Challenge (Grant), Carl Zeiss Meditec (Financial Support), Optovue (Financial Support), Aldeyra (Consultant), Allegran (Consultant), Aura Biosciences (Consultant), Bausch Health (Consultant), Beyeonics (Consultant), Merck (Consultant), Novartis (Consultant), Roche (Consultant), Eleven Oncology (Director of Entity), Eye-Point Pharma (Director of Entity), Hemera Biosciences (Stock). The remaining authors have no conflicting interests to disclose.